Topical tacrolimus in the management of atopic dermatitis in Japan

Masutaka Furue, Hiroshi Uchi, Yoichi Moroi, Sachiko Ogawa, Takeshi Nakahara, Kazunori Urabe

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Atopic dermatitis (AD) is a common, chronic, relapsing, severely pruritic, eczematous skin disease. Topical steroids are the mainstay of treatment. However, the adverse effects of steroids on hormonal function are the major obstacle for their use as long-term topical therapy. Topical calcineurin inhibitors, such as tacrolimus, not only complement existing treatment options but also overcome some of the drawbacks of topical steroid therapy and fulfill the long-term needs of patients in preventing disease progression. Short- and long-term efficacy and safety of topical tacrolimus has been widely recognized and it is also accepted as a first-line treatment for the inflammation of AD. In order to reduce the possible long-term adverse effects, it is important to monitor the clinical dose in daily clinics.

Original languageEnglish
Pages (from-to)118-126
Number of pages9
JournalDermatologic Therapy
Volume19
Issue number2
DOIs
Publication statusPublished - Mar 1 2006

Fingerprint

Tacrolimus
Atopic Dermatitis
Japan
Steroids
Eczematous Skin Diseases
Therapeutics
Disease Progression
Inflammation
Safety

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Topical tacrolimus in the management of atopic dermatitis in Japan. / Furue, Masutaka; Uchi, Hiroshi; Moroi, Yoichi; Ogawa, Sachiko; Nakahara, Takeshi; Urabe, Kazunori.

In: Dermatologic Therapy, Vol. 19, No. 2, 01.03.2006, p. 118-126.

Research output: Contribution to journalReview article

Furue, Masutaka ; Uchi, Hiroshi ; Moroi, Yoichi ; Ogawa, Sachiko ; Nakahara, Takeshi ; Urabe, Kazunori. / Topical tacrolimus in the management of atopic dermatitis in Japan. In: Dermatologic Therapy. 2006 ; Vol. 19, No. 2. pp. 118-126.
@article{5777463b3ad945028b8d96be26b0085e,
title = "Topical tacrolimus in the management of atopic dermatitis in Japan",
abstract = "Atopic dermatitis (AD) is a common, chronic, relapsing, severely pruritic, eczematous skin disease. Topical steroids are the mainstay of treatment. However, the adverse effects of steroids on hormonal function are the major obstacle for their use as long-term topical therapy. Topical calcineurin inhibitors, such as tacrolimus, not only complement existing treatment options but also overcome some of the drawbacks of topical steroid therapy and fulfill the long-term needs of patients in preventing disease progression. Short- and long-term efficacy and safety of topical tacrolimus has been widely recognized and it is also accepted as a first-line treatment for the inflammation of AD. In order to reduce the possible long-term adverse effects, it is important to monitor the clinical dose in daily clinics.",
author = "Masutaka Furue and Hiroshi Uchi and Yoichi Moroi and Sachiko Ogawa and Takeshi Nakahara and Kazunori Urabe",
year = "2006",
month = "3",
day = "1",
doi = "10.1111/j.1529-8019.2006.00064.x",
language = "English",
volume = "19",
pages = "118--126",
journal = "Dermatologic Therapy",
issn = "1396-0296",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Topical tacrolimus in the management of atopic dermatitis in Japan

AU - Furue, Masutaka

AU - Uchi, Hiroshi

AU - Moroi, Yoichi

AU - Ogawa, Sachiko

AU - Nakahara, Takeshi

AU - Urabe, Kazunori

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Atopic dermatitis (AD) is a common, chronic, relapsing, severely pruritic, eczematous skin disease. Topical steroids are the mainstay of treatment. However, the adverse effects of steroids on hormonal function are the major obstacle for their use as long-term topical therapy. Topical calcineurin inhibitors, such as tacrolimus, not only complement existing treatment options but also overcome some of the drawbacks of topical steroid therapy and fulfill the long-term needs of patients in preventing disease progression. Short- and long-term efficacy and safety of topical tacrolimus has been widely recognized and it is also accepted as a first-line treatment for the inflammation of AD. In order to reduce the possible long-term adverse effects, it is important to monitor the clinical dose in daily clinics.

AB - Atopic dermatitis (AD) is a common, chronic, relapsing, severely pruritic, eczematous skin disease. Topical steroids are the mainstay of treatment. However, the adverse effects of steroids on hormonal function are the major obstacle for their use as long-term topical therapy. Topical calcineurin inhibitors, such as tacrolimus, not only complement existing treatment options but also overcome some of the drawbacks of topical steroid therapy and fulfill the long-term needs of patients in preventing disease progression. Short- and long-term efficacy and safety of topical tacrolimus has been widely recognized and it is also accepted as a first-line treatment for the inflammation of AD. In order to reduce the possible long-term adverse effects, it is important to monitor the clinical dose in daily clinics.

UR - http://www.scopus.com/inward/record.url?scp=33645881082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645881082&partnerID=8YFLogxK

U2 - 10.1111/j.1529-8019.2006.00064.x

DO - 10.1111/j.1529-8019.2006.00064.x

M3 - Review article

C2 - 16669995

AN - SCOPUS:33645881082

VL - 19

SP - 118

EP - 126

JO - Dermatologic Therapy

JF - Dermatologic Therapy

SN - 1396-0296

IS - 2

ER -